LEGN Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$49.25median target· current $21.89 (+125.0%)15 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—Forward 136.99
EPS (TTM)$-0.510.0% YoY
Profit margin-7.2%HEALTHCARE
Market cap$4.11BMid cap
Valuation
- Forward P/E
- 136.99
- PEG ratio
- —
- P/B
- 3.29
- P/S (TTM)
- 3.23
- EV/EBITDA
- 291.75
Profitability & growth
- ROE (TTM)
- -8.1%
- Operating margin
- 14.9%
- Revenue growth YoY
- 51.9%
- Dividend yield
- —
- Beta
- 0.39
Last earnings
Aug 10, 2026 · Estimate $0.12 · Reported $0.09
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Legend Biotech Corp
Company profileLegend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in North America and internationally.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 2101 COTTONTAIL LANE, SOMERSET, NJ
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$4.11B
Shares outstanding$194.5M
52W high$37.50
52W low$16.24
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent